LINAFEXOR Trademark

Trademark Overview


On Monday, October 11, 2021, a trademark application was filed for LINAFEXOR with the United States Patent and Trademark Office. The USPTO has given the LINAFEXOR trademark a serial number of 79324763. The federal status of this trademark filing is REGISTERED as of Tuesday, June 27, 2023. This trademark is owned by Cascade Pharmaceuticals, Inc. The LINAFEXOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of immune, inflammatory and metabolic diseases, namely, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease for medical purposes; organotherapy preparations; enzyme preparations for medical purposes; medicines for the treatment of immune, inflammatory and metabolic diseases, namely, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease, for human purposes; chemical preparations for medical purposes, namely for immune, inflammatory and metabolic diseases, particularly, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease; surgical implants comprised of living tissues; stem cells for medical purposes; biological tissue cultures...
linafexor

General Information


Serial Number79324763
Word MarkLINAFEXOR
Filing DateMonday, October 11, 2021
Status700 - REGISTERED
Status DateTuesday, June 27, 2023
Registration Number7088788
Registration DateTuesday, June 27, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of immune, inflammatory and metabolic diseases, namely, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease for medical purposes; organotherapy preparations; enzyme preparations for medical purposes; medicines for the treatment of immune, inflammatory and metabolic diseases, namely, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease, for human purposes; chemical preparations for medical purposes, namely for immune, inflammatory and metabolic diseases, particularly, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), cholestatic liver disease, inflammatory bowel disease, chronic kidney disease; surgical implants comprised of living tissues; stem cells for medical purposes; biological tissue cultures for medical purposes; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; the foregoing featuring farnesoid X receptor agonists

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 3, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCascade Pharmaceuticals, Inc
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCN

Party NameCascade Pharmaceuticals, Inc
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCN

Party NameCascade Pharmaceuticals, Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Trademark Events


Event DateEvent Description
Wednesday, September 27, 2023FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, September 27, 2023FINAL DISPOSITION PROCESSED
Wednesday, September 27, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 27, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, June 27, 2023REGISTERED-PRINCIPAL REGISTER
Monday, April 24, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, April 12, 2023NOTIFICATION PROCESSED BY IB
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, April 5, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, March 22, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 22, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 3, 2023EXAMINER'S AMENDMENT ENTERED
Friday, March 3, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 3, 2023EXAMINERS AMENDMENT E-MAILED
Friday, March 3, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, February 8, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 7, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 7, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 30, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, January 30, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 30, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Monday, January 30, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, January 30, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, January 30, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 5, 2022REFUSAL PROCESSED BY IB
Monday, August 15, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, August 15, 2022REFUSAL PROCESSED BY MPU
Tuesday, July 26, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, July 25, 2022NON-FINAL ACTION WRITTEN
Friday, July 15, 2022ASSIGNED TO EXAMINER
Tuesday, November 9, 2021APPLICATION FILING RECEIPT MAILED
Friday, November 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 4, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB